Baricitinib is a JAK 1 and 2 inhibitor. They failed the primary endpoint of disease progression in one trial. Their second trial that it was approved on added one day in time to recovery from 8 to 7 p=.03. The FDA approved based on safety and it may be effective. It does have a list of serious side effects.

Leronlimab downregulates JAK 1 and 2 on top of everything else. Give us a 1,000 person mild/moderate trial like baractinib and we'll blow those results out of the water.